Selective desensitization to seminal plasma protein fractions after immunotherapy for postcoital anaphylaxis
A 24-year-old white woman reported sexual intercourse-related pruritus, hives, wheezing, and dyspnea within 5 minutes after ejaculation. Systemic reactions (SRs) were prevented by use of condoms. Prick testing confirmed sensitization to five Sephadex G-100-separated fractions of her husband's s...
Gespeichert in:
Veröffentlicht in: | Journal of allergy and clinical immunology 1990-12, Vol.86 (6), p.954-960 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 960 |
---|---|
container_issue | 6 |
container_start_page | 954 |
container_title | Journal of allergy and clinical immunology |
container_volume | 86 |
creator | Mittman, Robert J. Bernstein, David I. Adler, Thomas R. Korbee, Leslie Nath, Veena Gallagher, Joan S. Bernstein, I. Leonard |
description | A 24-year-old white woman reported sexual intercourse-related pruritus, hives, wheezing, and dyspnea within 5 minutes after ejaculation. Systemic reactions (SRs) were prevented by use of condoms. Prick testing confirmed sensitization to five Sephadex G-100-separated fractions of her husband's seminal plasma. The intradermal end point threshold concentrations (ETC) were 10
−4 and 10
−1 μg of protein per milliliter to fractions 2 and 3, respectively. Leukocyte histamine release studies exhibited 100% release to fraction 2 and 37% release to fraction 3. A 2-day protocol of rapid immunotherapy (IT) was performed with subcutaneous incremental doses of human seminal plasma (HuSePl) fractions 2 and 3. The patient experienced an SR after receiving a cumulative dose of 38.55 μg of fraction 2 on day 1. On day 2, rapid IT with fraction 2 was administered until the patient experienced a mild SR after havin received a cumulative dose of 102.8 μg. There was a one-log
10 increase in the intradermal ETC to both fractions 2 and 3 at the end of day 2. It was continued three times weekly for 4 months until the patient tolerated 100 μg doses of both fractions 2 and 3. At 4 months, coitus was resumed without SRs, and HuSePl IT was stopped. The intradermal ETC to fractions 1, 3, 4, and 5 was increased 6 months after cessation of HuSePl injections, but there was a one-log decrease in the ETC to fraction 2. Our experience demonstrated that systemic tolerance can be achieved by parenteral administration of selected HuSePl fractions. Partial immunologic desensitization of patients with anaphylactic sensitivity can be achieved. This appears to be selective for most, but not all, allergenic fractions contained in HuSePl. |
doi_str_mv | 10.1016/S0091-6749(05)80159-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80187886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674905801599</els_id><sourcerecordid>15885420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-710b32ab264fb85d264f1b2baafcfb28a1ad7d4210ae1ae9f103d77f2f55d0843</originalsourceid><addsrcrecordid>eNqFkc1rHSEUxaU0pK9p_4SAm5ZmMan6xhldlRD6EQh0kXYtd5wrsTjjVH0hr399fB-ky6wucn_nejiHkHPOLjnj3ec7xjRvur7Vn5i8UIxL3ehXZMWZ7ptOCfmarJ6RN-Rtzn9Yfa-VPiWnQnSik2xFwh0GtMU_IB0x45x98f-g-DjTEmnGyc8Q6BIgT0CXFAv6mboEdodkCq5gon6aNnMs95hg2VIXE11iLjb6UrUww3K_DfDo8zty4iBkfH-cZ-T3t6-_rn80tz-_31xf3Ta2VX1pes6GtYBBdK0blBx3kw9iAHDWDUIBh7EfW8EZIAfUjrP12PdOOClHptr1Gfl4uFsN_91gLmby2WIIMGPcZFPDUr1S3Ysgl0rJVrAKygNoU8w5oTNL8hOkreHM7Oow-zrMLmvDpNnXYXTVnR8_2AwTjs-qY_51_-G4h2wh1GBn6_P_47rTiu2NfjlwWGN78JhMth5ni6NPtT4zRv-Ckyd3BKpU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15885420</pqid></control><display><type>article</type><title>Selective desensitization to seminal plasma protein fractions after immunotherapy for postcoital anaphylaxis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mittman, Robert J. ; Bernstein, David I. ; Adler, Thomas R. ; Korbee, Leslie ; Nath, Veena ; Gallagher, Joan S. ; Bernstein, I. Leonard</creator><creatorcontrib>Mittman, Robert J. ; Bernstein, David I. ; Adler, Thomas R. ; Korbee, Leslie ; Nath, Veena ; Gallagher, Joan S. ; Bernstein, I. Leonard</creatorcontrib><description>A 24-year-old white woman reported sexual intercourse-related pruritus, hives, wheezing, and dyspnea within 5 minutes after ejaculation. Systemic reactions (SRs) were prevented by use of condoms. Prick testing confirmed sensitization to five Sephadex G-100-separated fractions of her husband's seminal plasma. The intradermal end point threshold concentrations (ETC) were 10
−4 and 10
−1 μg of protein per milliliter to fractions 2 and 3, respectively. Leukocyte histamine release studies exhibited 100% release to fraction 2 and 37% release to fraction 3. A 2-day protocol of rapid immunotherapy (IT) was performed with subcutaneous incremental doses of human seminal plasma (HuSePl) fractions 2 and 3. The patient experienced an SR after receiving a cumulative dose of 38.55 μg of fraction 2 on day 1. On day 2, rapid IT with fraction 2 was administered until the patient experienced a mild SR after havin received a cumulative dose of 102.8 μg. There was a one-log
10 increase in the intradermal ETC to both fractions 2 and 3 at the end of day 2. It was continued three times weekly for 4 months until the patient tolerated 100 μg doses of both fractions 2 and 3. At 4 months, coitus was resumed without SRs, and HuSePl IT was stopped. The intradermal ETC to fractions 1, 3, 4, and 5 was increased 6 months after cessation of HuSePl injections, but there was a one-log decrease in the ETC to fraction 2. Our experience demonstrated that systemic tolerance can be achieved by parenteral administration of selected HuSePl fractions. Partial immunologic desensitization of patients with anaphylactic sensitivity can be achieved. This appears to be selective for most, but not all, allergenic fractions contained in HuSePl.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/S0091-6749(05)80159-9</identifier><identifier>PMID: 2262650</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adult ; Anaphylaxis - diagnosis ; Anaphylaxis - etiology ; Anaphylaxis - therapy ; Biological and medical sciences ; Blood Proteins - immunology ; Chemical Fractionation ; Coitus ; Desensitization, Immunologic ; Female ; Humans ; Immunologic Tests ; Immunopathology ; Immunotherapy ; Immunotherapy (general aspects) ; Medical sciences ; Semen - immunology</subject><ispartof>Journal of allergy and clinical immunology, 1990-12, Vol.86 (6), p.954-960</ispartof><rights>1990 Mosby-Year Book, Inc.</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-710b32ab264fb85d264f1b2baafcfb28a1ad7d4210ae1ae9f103d77f2f55d0843</citedby><cites>FETCH-LOGICAL-c487t-710b32ab264fb85d264f1b2baafcfb28a1ad7d4210ae1ae9f103d77f2f55d0843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0091-6749(05)80159-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19698086$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2262650$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mittman, Robert J.</creatorcontrib><creatorcontrib>Bernstein, David I.</creatorcontrib><creatorcontrib>Adler, Thomas R.</creatorcontrib><creatorcontrib>Korbee, Leslie</creatorcontrib><creatorcontrib>Nath, Veena</creatorcontrib><creatorcontrib>Gallagher, Joan S.</creatorcontrib><creatorcontrib>Bernstein, I. Leonard</creatorcontrib><title>Selective desensitization to seminal plasma protein fractions after immunotherapy for postcoital anaphylaxis</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>A 24-year-old white woman reported sexual intercourse-related pruritus, hives, wheezing, and dyspnea within 5 minutes after ejaculation. Systemic reactions (SRs) were prevented by use of condoms. Prick testing confirmed sensitization to five Sephadex G-100-separated fractions of her husband's seminal plasma. The intradermal end point threshold concentrations (ETC) were 10
−4 and 10
−1 μg of protein per milliliter to fractions 2 and 3, respectively. Leukocyte histamine release studies exhibited 100% release to fraction 2 and 37% release to fraction 3. A 2-day protocol of rapid immunotherapy (IT) was performed with subcutaneous incremental doses of human seminal plasma (HuSePl) fractions 2 and 3. The patient experienced an SR after receiving a cumulative dose of 38.55 μg of fraction 2 on day 1. On day 2, rapid IT with fraction 2 was administered until the patient experienced a mild SR after havin received a cumulative dose of 102.8 μg. There was a one-log
10 increase in the intradermal ETC to both fractions 2 and 3 at the end of day 2. It was continued three times weekly for 4 months until the patient tolerated 100 μg doses of both fractions 2 and 3. At 4 months, coitus was resumed without SRs, and HuSePl IT was stopped. The intradermal ETC to fractions 1, 3, 4, and 5 was increased 6 months after cessation of HuSePl injections, but there was a one-log decrease in the ETC to fraction 2. Our experience demonstrated that systemic tolerance can be achieved by parenteral administration of selected HuSePl fractions. Partial immunologic desensitization of patients with anaphylactic sensitivity can be achieved. This appears to be selective for most, but not all, allergenic fractions contained in HuSePl.</description><subject>Adult</subject><subject>Anaphylaxis - diagnosis</subject><subject>Anaphylaxis - etiology</subject><subject>Anaphylaxis - therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Proteins - immunology</subject><subject>Chemical Fractionation</subject><subject>Coitus</subject><subject>Desensitization, Immunologic</subject><subject>Female</subject><subject>Humans</subject><subject>Immunologic Tests</subject><subject>Immunopathology</subject><subject>Immunotherapy</subject><subject>Immunotherapy (general aspects)</subject><subject>Medical sciences</subject><subject>Semen - immunology</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1rHSEUxaU0pK9p_4SAm5ZmMan6xhldlRD6EQh0kXYtd5wrsTjjVH0hr399fB-ky6wucn_nejiHkHPOLjnj3ec7xjRvur7Vn5i8UIxL3ehXZMWZ7ptOCfmarJ6RN-Rtzn9Yfa-VPiWnQnSik2xFwh0GtMU_IB0x45x98f-g-DjTEmnGyc8Q6BIgT0CXFAv6mboEdodkCq5gon6aNnMs95hg2VIXE11iLjb6UrUww3K_DfDo8zty4iBkfH-cZ-T3t6-_rn80tz-_31xf3Ta2VX1pes6GtYBBdK0blBx3kw9iAHDWDUIBh7EfW8EZIAfUjrP12PdOOClHptr1Gfl4uFsN_91gLmby2WIIMGPcZFPDUr1S3Ysgl0rJVrAKygNoU8w5oTNL8hOkreHM7Oow-zrMLmvDpNnXYXTVnR8_2AwTjs-qY_51_-G4h2wh1GBn6_P_47rTiu2NfjlwWGN78JhMth5ni6NPtT4zRv-Ckyd3BKpU</recordid><startdate>19901201</startdate><enddate>19901201</enddate><creator>Mittman, Robert J.</creator><creator>Bernstein, David I.</creator><creator>Adler, Thomas R.</creator><creator>Korbee, Leslie</creator><creator>Nath, Veena</creator><creator>Gallagher, Joan S.</creator><creator>Bernstein, I. Leonard</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19901201</creationdate><title>Selective desensitization to seminal plasma protein fractions after immunotherapy for postcoital anaphylaxis</title><author>Mittman, Robert J. ; Bernstein, David I. ; Adler, Thomas R. ; Korbee, Leslie ; Nath, Veena ; Gallagher, Joan S. ; Bernstein, I. Leonard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-710b32ab264fb85d264f1b2baafcfb28a1ad7d4210ae1ae9f103d77f2f55d0843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adult</topic><topic>Anaphylaxis - diagnosis</topic><topic>Anaphylaxis - etiology</topic><topic>Anaphylaxis - therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Proteins - immunology</topic><topic>Chemical Fractionation</topic><topic>Coitus</topic><topic>Desensitization, Immunologic</topic><topic>Female</topic><topic>Humans</topic><topic>Immunologic Tests</topic><topic>Immunopathology</topic><topic>Immunotherapy</topic><topic>Immunotherapy (general aspects)</topic><topic>Medical sciences</topic><topic>Semen - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mittman, Robert J.</creatorcontrib><creatorcontrib>Bernstein, David I.</creatorcontrib><creatorcontrib>Adler, Thomas R.</creatorcontrib><creatorcontrib>Korbee, Leslie</creatorcontrib><creatorcontrib>Nath, Veena</creatorcontrib><creatorcontrib>Gallagher, Joan S.</creatorcontrib><creatorcontrib>Bernstein, I. Leonard</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mittman, Robert J.</au><au>Bernstein, David I.</au><au>Adler, Thomas R.</au><au>Korbee, Leslie</au><au>Nath, Veena</au><au>Gallagher, Joan S.</au><au>Bernstein, I. Leonard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selective desensitization to seminal plasma protein fractions after immunotherapy for postcoital anaphylaxis</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>1990-12-01</date><risdate>1990</risdate><volume>86</volume><issue>6</issue><spage>954</spage><epage>960</epage><pages>954-960</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>A 24-year-old white woman reported sexual intercourse-related pruritus, hives, wheezing, and dyspnea within 5 minutes after ejaculation. Systemic reactions (SRs) were prevented by use of condoms. Prick testing confirmed sensitization to five Sephadex G-100-separated fractions of her husband's seminal plasma. The intradermal end point threshold concentrations (ETC) were 10
−4 and 10
−1 μg of protein per milliliter to fractions 2 and 3, respectively. Leukocyte histamine release studies exhibited 100% release to fraction 2 and 37% release to fraction 3. A 2-day protocol of rapid immunotherapy (IT) was performed with subcutaneous incremental doses of human seminal plasma (HuSePl) fractions 2 and 3. The patient experienced an SR after receiving a cumulative dose of 38.55 μg of fraction 2 on day 1. On day 2, rapid IT with fraction 2 was administered until the patient experienced a mild SR after havin received a cumulative dose of 102.8 μg. There was a one-log
10 increase in the intradermal ETC to both fractions 2 and 3 at the end of day 2. It was continued three times weekly for 4 months until the patient tolerated 100 μg doses of both fractions 2 and 3. At 4 months, coitus was resumed without SRs, and HuSePl IT was stopped. The intradermal ETC to fractions 1, 3, 4, and 5 was increased 6 months after cessation of HuSePl injections, but there was a one-log decrease in the ETC to fraction 2. Our experience demonstrated that systemic tolerance can be achieved by parenteral administration of selected HuSePl fractions. Partial immunologic desensitization of patients with anaphylactic sensitivity can be achieved. This appears to be selective for most, but not all, allergenic fractions contained in HuSePl.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>2262650</pmid><doi>10.1016/S0091-6749(05)80159-9</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-6749 |
ispartof | Journal of allergy and clinical immunology, 1990-12, Vol.86 (6), p.954-960 |
issn | 0091-6749 1097-6825 |
language | eng |
recordid | cdi_proquest_miscellaneous_80187886 |
source | MEDLINE; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals |
subjects | Adult Anaphylaxis - diagnosis Anaphylaxis - etiology Anaphylaxis - therapy Biological and medical sciences Blood Proteins - immunology Chemical Fractionation Coitus Desensitization, Immunologic Female Humans Immunologic Tests Immunopathology Immunotherapy Immunotherapy (general aspects) Medical sciences Semen - immunology |
title | Selective desensitization to seminal plasma protein fractions after immunotherapy for postcoital anaphylaxis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A39%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selective%20desensitization%20to%20seminal%20plasma%20protein%20fractions%20after%20immunotherapy%20for%20postcoital%20anaphylaxis&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Mittman,%20Robert%20J.&rft.date=1990-12-01&rft.volume=86&rft.issue=6&rft.spage=954&rft.epage=960&rft.pages=954-960&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/S0091-6749(05)80159-9&rft_dat=%3Cproquest_cross%3E15885420%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15885420&rft_id=info:pmid/2262650&rft_els_id=S0091674905801599&rfr_iscdi=true |